HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in ADC Online Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

Cardiac

G150 CONTRIBUTING TO DEVELOPMENTALLY NORMAL PHYSIOLOGICAL VALUES FOR CHILDREN AND ADOLESCENTS: AN ANALYSIS OF BASELINE QTC INTERVALS IN PAEDIATRIC PATIENTS WITH ADHD ON ENTRY TO A PHARMACOTHERAPY CLINICAL TRIAL PROGRAMME
A. Furr¹, S. Zhang², A. Allen², S. Ball³, S. Prasad⁴.¹Indiana University School of Medicine, Indianapolis, IN, USA; ²Lilly Research Laboratories, Indianapolis, IN, USA; ³Medfocus, Indianapolis, IN, USA; ⁴Eli Lilly and Company, Ltd, Basingstoke, Hampshire, UK

Aims: The effect of medications on cardiac function is an area of increasing focus in the treatment of children with chronic conditions, as cardiac parameters such as the QT interval may be affected resulting in a potentially increased risk for adverse cardiac events. Given their developmental progression there is continuing debate about normal values of QTc in children and adolescents. This analysis, from all paediatric patient entering the atomoxetine clinical trial program provides age appropriate ECG baseline values from approximately 6000 children and adolescents who presented with the neurodevelopmental condition attention-deficit/hyperactivity disorder (ADHD), and contributes a significant body of information to normal values for QTc intervals in a paediatric . . . [Full text of this article]